SL
MNPR icon

Siren LLC’s Monopar Therapeutics MNPR Stock Holding History

Siren LLC’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.8M Buy
270,118
+57,820
+27% +$3.49M 0.41% 53
2025
Q4 		$13.9M Buy
+212,298
New +$17.3M 0.41% 45

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Siren LLC's MNPR Position: Q1 2026 in Review

Siren LLC increased its Monopar Therapeutics (MNPR) stake by 27% in Q1 2026, buying an estimated $3.49M and bringing the position to 270,118 shares worth $14.8M. The position accounts for 0.41% of the portfolio, ranked #53.

Siren LLC first reported a position in MNPR in Q4 2025 and has held it in 2 quarters since. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Siren LLC held 270,118 shares of Monopar Therapeutics worth $14.8M as of Q1 2026.
  • Siren LLC bought 57,820 Monopar Therapeutics shares in Q1 2026, an estimated $3.49M.
  • Monopar Therapeutics made up 0.41% of Siren LLC's portfolio in Q1 2026, its #53 holding.
  • Siren LLC first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Siren LLC's 13F filing for Q1 2026, filed 14 May 2026.